Myron Kaplan - 23 Oct 2025 Form 4 Insider Report for CorMedix Inc. (CRMD)

Role: Director
Signature: /s/ Myron Kaplan
Issuer symbol: CRMD
Transactions as of: 23 Oct 2025
Net transactions value: +$275,500
Form type: 4
Filing time: 27 Oct 2025, 21:30:10 UTC
Previous filing: 22 Jan 2025
Next filing: 27 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kaplan Myron	Director	C/O CORMEDIX INC., 300 CONNELL DRIVE, BERKELEY HEIGHTS	/s/ Myron Kaplan	27 Oct 2025	0001672645

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRMD	Common Stock	Purchase	$275,500	+25,000	+14%	$11.02	201,034	23 Oct 2025	Direct	F1
holding	CRMD	Common Stock						20,000	23 Oct 2025	Spouse	F2
holding	CRMD	Common Stock						10,000	23 Oct 2025	Spouse as Guardian for Grandchildren	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.01 to $11.03, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F2	The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.01 to $11.03, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.